0001493152-23-005863.txt : 20230223 0001493152-23-005863.hdr.sgml : 20230223 20230223152457 ACCESSION NUMBER: 0001493152-23-005863 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230221 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MyMD Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001321834 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36268 FILM NUMBER: 23659260 BUSINESS ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 623 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 856-848-8698 MAIL ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 623 CITY: BALTIMORE STATE: MD ZIP: 21205 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences, Inc. DATE OF NAME CHANGE: 20170413 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences Inc DATE OF NAME CHANGE: 20050325 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 21, 2023

MyMD Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

New Jersey

001-36268

22-2983783

(State or other jurisdiction

of incorporation)

(Commission

File No.)

(IRS Employer

Identification No.)

MyMD Pharmaceuticals, Inc.

855 N. Wolfe Street, Suite 601

Baltimore, MD 21205

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (856) 848-8698

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, no par value per share		MYMD		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

As previously reported, on February 21, 2023, the Company entered into a definitive agreement (the “Securities Purchase Agreement”) with certain accredited investors to sell in a registered direct offering (i) an aggregate of 15,000 shares of the Company’s newly-designated Series F Convertible Preferred Stock with a stated value of $1,000 per share, convertible into shares of the Company’s common stock, no par value (the “Common Stock”), pursuant to the terms of the Securities Purchase Agreement, and (ii) warrants to acquire up to an aggregate of 6,651,885 shares of Common Stock, subject to adjustment.

The legal opinions of DLA Piper LLP (US) and Haynes and Boone, LLP, relating to the legality of the issuance and sale of the securities in the offering are attached as Exhibit 5.1 and Exhibit 5.2, respectively, to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
5.1		Opinion of DLA Piper LLP (US)
5.2		Opinion of Haynes and Boone, LLP
23.1		Consent of DLA Piper LLP (US) (included in Exhibit 5.1)
23.2		Consent of Haynes and Boone, LLP (included in Exhibit 5.2)
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MYMD PHARMACEUTICALS, INC.

Date: February 23, 2023	By:	/s/ Chris Chapman
		Chris Chapman, M.D.
		President

EX-5.1 2 ex5-1.htm

Exhibit 5.1

	DLA Piper LLP (US)
	51 John F. Kennedy Parkway, Suite 120
	Short Hills, New Jersey 07078
	www.dlapiper.com

	T: 973-520-2550
	F: 973-520-2551

	Attorneys Responsible for Short Hills Office:

	Emilio Ragosa

February 23, 2023

MyMD Pharmaceuticals, Inc.

855 N. Wolfe Street, Suite 601
Baltimore, MD 21205

Re:

MyMD Pharmaceuticals, Inc., Registration Statement on Form S-3

Ladies and Gentlemen:

We have acted as New Jersey counsel to MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), in connection with the sale by the Company of (i) 15,000 shares of the Company’s Series F Convertible Preferred Stock, without par value and with stated value equal to $1,000 per share (the “Shares”), which, pursuant to the terms of the Securities Purchase Agreement (as defined below), are convertible into shares (the “Conversion Shares”) of the Company’s common stock, without par value (“Common Stock”) and (ii) warrants (the “Warrants”) to purchase an aggregate of up to, subject to adjustment, 6,651,885 shares of Common Stock (the “Warrant Shares” and, together with the Shares, the Conversion Shares and the Warrants, the “Securities”) pursuant to that certain registration statement on Form S-3 (Registration No. 333-254698), as filed by the Company under the Securities Act of 1933, as amended (the “Securities Act”), and declared effective by the Securities and Exchange Commission (the “SEC”) on May 11, 2021 (including information deemed incorporated by reference therein in accordance with the applicable rules of the SEC, the “Registration Statement”), and the prospectus contained therein, as supplemented by the prospectus supplement dated February 21, 2023 (the “Prospectus Supplement”), pursuant to the Securities Purchase Agreement (the “Securities Purchase Agreement”), dated February 21, 2023 between the Company and each purchaser identified on the signature pages thereto. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Securities Purchase Agreement.

In connection with this opinion letter, we have examined the Registration Statement (including the prospectus contained therein), the Prospectus Supplement, the Securities Purchase Agreement, the Certificate of Designations submitted to the Secretary of State of New Jersey on February 22, 2023, the form of Warrant and originals, or copies certified or otherwise identified to our satisfaction, of the Certificate of Incorporation, the Bylaws, the Unanimous Written Consent of the Board of Directors of the Company dated February 21, 2023, the minutes of meetings of the stockholders and the Board of Directors, as provided to us by the Company, and such other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.

We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents submitted to us as copies. We have also assumed that upon (i) the due and proper exercise of the Warrants and payment in full to the Company of the exercise price for the Warrant Shares required therefor, in accordance with the terms of the Warrants, a sufficient number of shares of Common Stock will be authorized and available for issuance and (ii) conversion of the Shares into the Conversion Shares in accordance with the Certificate of Designations, a sufficient number of shares of Common Stock will be authorized and available for issuance

Based upon the foregoing, we are of the opinion that (i) the Shares and the Warrants have been duly authorized and are validly issued, fully paid and nonassessable, (ii) the Conversion Shares and the Warrant Shares have been duly authorized and reserved for issuance by all necessary corporate action on the part of the Company, (iii) the Warrant Shares, if and when issued and delivered by the Company in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, and (iv) the Conversion Shares, if and when issued and delivered by the Company in accordance with the terms of the Certificate of Designations, will be validly issued, fully paid and nonassessable.

The opinion expressed herein is limited to the New Jersey Business Corporation Act.

We hereby consent to the use of this opinion as Exhibit 5.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 23, 2023 and its incorporation by reference into the Registration Statement and to the reference to us under the caption “Legal Matters” in the Prospectus Supplement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the U.S. Securities and Exchange Commission thereunder.

Very truly yours,

/s/ DLA Piper LLP (US)

EX-5.2 3 ex5-2.htm

Exhibit 5.2

February 23, 2023

MyMD Pharmaceuticals, Inc.
855 N. Wolfe Street, Suite 601
Baltimore, MD 21205

Ladies and Gentlemen:

We have acted as counsel for MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), in connection with the filing with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Act”) of the Company’s prospectus supplement, dated February 21, 2023 (the “Prospectus Supplement”), forming part of the registration statement on Form S-3 (Registration No. 333-254698), initially filed by the Company with the Commission on March 25, 2021, amended on April 28, 2021 and declared effective on May 11, 2021 (the “Registration Statement”). The Prospectus Supplement relates to the proposed sale of (i) an aggregate of 15,000 shares of the Company’s newly-designated Series F Convertible Preferred Stock with a stated value of $1,000 per share (the “Preferred Shares”), convertible into shares (the “Conversion Shares”) of the Company’s common stock, no par value (the “Common Stock”) pursuant to the terms of the Securities Purchase Agreement (as defined below), and (ii) 6,651,885 warrants (the “Warrants”) to acquire up to an aggregate of 6,651,885 shares of Common Stock, subject to adjustment (the “Warrant Shares”).

The Shares and the Warrants are being sold pursuant a securities purchase agreement, dated February 21, 2023, between the Company and each purchaser named therein (the “Securities Purchase Agreement”).

In rendering the opinion expressed herein, we have examined and relied upon the originals, or copies certified or otherwise identified to our satisfaction, of (i) the Company’s Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws, each as amended and/or restated to date (“Company Charter Documents”); (ii) certain resolutions of the Board of Directors of the Company related to the filing of the Prospectus Supplement, the authorization and issuance of the Shares and related matters; (iii) the Registration Statement, including the prospectus, and all exhibits thereto; (iv) the Prospectus Supplement and the prospectus included in the Registration Statement (the “Base Prospectus” and together with the Prospectus Supplement, the “Prospectus”); (v) the Securities Purchase Agreement; (vi) the Warrants and (vii) such other corporate records of the Company, as we have deemed necessary or appropriate for the purposes of the opinion hereafter expressed.

MyMD Pharmaceuticals, Inc.

February 23, 2023

Page 2

As to questions of fact material to the opinion expressed below, we have, without independent verification of their accuracy, relied to the extent we deem reasonably appropriate upon the representations and warranties of the Company contained in such documents, records, certificates, instruments or representations furnished or made available to us by the Company.

In making the foregoing examination, we have assumed (i) the genuineness of all signatures, (ii) the authenticity of all documents submitted to us as originals, (iii) the conformity to original documents of all documents submitted to us as certified or photostatic copies, (iv) that all agreements or instruments we have examined are the valid, binding and enforceable obligations of the parties thereto, and (v) that all factual information on which we have relied was accurate and complete.

Based upon the foregoing and subject to the assumptions and qualifications stated herein, we are of the opinion that when the Warrants have been duly executed by the Company and the Warrants have been issued and sold pursuant to the Securities Purchase Agreement, against payment in full of the consideration payable therefor, the Warrants will constitute valid and legally binding obligations of the Company.

The opinion expressed herein is limited to the laws of the State of New York as in effect on the date hereof, and we have not considered, and express no opinion on, any other laws or the laws of any other jurisdiction.

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.2 to the Current Report on Form 8-K filed with the Commission on February 23, 2023 and to the reference to our firm under the heading “Legal Matters” in the Prospectus. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Haynes and Boone, LLP

Haynes and Boone, LLP

EX-101.SCH 4 mymd-20230221.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mymd-20230221_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 mymd-20230221_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 21, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 21, 2023
Entity File Number	001-36268
Entity Registrant Name	MyMD Pharmaceuticals, Inc.
Entity Central Index Key	0001321834
Entity Tax Identification Number	22-2983783
Entity Incorporation, State or Country Code	NJ
Entity Address, Address Line One	MyMD Pharmaceuticals, Inc.
Entity Address, Address Line Two	855 N. Wolfe Street
Entity Address, Address Line Three	Suite 601
Entity Address, City or Town	Baltimore
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21205
City Area Code	(856)
Local Phone Number	848-8698
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, no par value per share
Trading Symbol	MYMD
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001321834 2023-02-21 2023-02-21 iso4217:USD shares iso4217:USD shares 0001321834 false 8-K 2023-02-21 MyMD Pharmaceuticals, Inc. NJ 001-36268 22-2983783 MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street Suite 601 Baltimore MD 21205 (856) 848-8698 false false false false Common stock, no par value per share MYMD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mymd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex5-1.htm ex5-2.htm mymd-20230221.xsd mymd-20230221_lab.xml mymd-20230221_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "mymd-20230221_lab.xml" ] }, "presentationLink": { "local": [ "mymd-20230221_pre.xml" ] }, "schema": { "local": [ "mymd-20230221.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MYMD", "nsuri": "http://mymd.com/20230221", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-21to2023-02-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://mymd.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-21to2023-02-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mymd.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-005863-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-005863-xbrl.zip M4$L#!!0 ( !M[5U;QV9AII@H -$^ ) 97@U+3$N:'1M[5MK4]O& M&O[N&?^'+>/^^O.\NY(L M^9)+"PWDD$D(EM[=?:_/>Y'<>3VXO#BJ5CJO3X][^)_1G\[@?'!Q>M39!'..6EN-)?)?,=[I'I[<3.91QM=)NM#H[ MW:-[DN0G&=ZS+.L-,3CN7IRRD].+B_[5\]OFK19Q) M/YX0:?/'0S94VA>Z[JD@X)$!0]EO6S8<.H/KKS_@1NA8>CS(U#54<:RF6VE\ M=0:]O\WS?O/'>U3[H'<'+/YTMRSV+HX=3U/EDGV_)UFPV:_C(-@1M#4]-'[0U,AW^,^45=GEP M$G[W_C8X<&R\>K%7;^\VZ[OM]A-"?U.VSE8MTGK0%GE"@4?O<\=0D0[%W#AN MKH6)5&CD,!"@U8&]'(^F)@R>/?/+(^V3K%,ND2MV1CY7AZSUNQTX$ MCNYTFI2IY(Z'/W>:),10)US/JY7=O1K;;>[NW=?(ZO$,U^Z2T\OY9:]:N9IP M/>6>2&SX@OP\]!J/@?V7[7:U\J;!WJM@)%@_UD+$60N^WVQUNA0]71[$2Q5"*_CL9B*,&;X<*;TE/7K0*EW1\L2WB>8PZFX]V&L51+ZY%A* M'[#9!&'P>&#M7Q'A@OM2H/KCH<]^@B6IGP&\&X%PN?<5.HR.5!NUV/!'L6>!_3-0A M@OY$32,>SBEBGVE[\7F-R1!+PE!XM*):F[J0J1';EL]9 MJUUK-IO,@!O(BHL%FF?:T,;&"HR[9[@16MBF]N-*BY'0&H+V8^5]J#$Z3B4Q MB[AF-SQ(H(?03[DP!#E^>EE\3+A5Q'];]G!Z5F 96!:R;[DJRPBK>9,:BQ)M M$@X(PS:T*!9ZFO/?%UZB94P\7R7:FW #RQR/D6LMZFW#,KX8R1 <#46@9MB6 M3O<*TLD0&Z=:65$]D1F+I"L,;E*AIZ93LHG9I*OMDFVG%J9!6MJ;,&!;PFHS MKC6$7V'M?7J]M J"1*D6L /C8RAB#'-4*^ UB7"_QDPR_!-N0[3=\Q5 J5M5[M[=F5',?Y6+OLYZ45)7]WP.\++^ 4:F(T MHNB^R<.YL)0(3V]AYW!LV9I*8]8@1__TI.RP(;OD<]9JV6ZE!0<+O2#Q93A& M$(R@%N[0Q*?H\7$M0R6G XL"(O0$L:,%E(R_W .1S^EJ;FH>10&@CH)+)\$" M;,#/LEG75RMK]$++2OB=0OM_4#.W=U]M'45:F0@:2R@"0_(!X6>,6HN8!&S9 M[1Q!7F+3#5(WCQ,@:L3' MX,#J.U:IZAKL. B8QR,9(\G_1?:PV!TJQ J1SB28S? Y]2G #Q;9Y$HG3 4/ MR4&Y\;0<9B:%IJ3E%X'\*?GOK5%\JI[^@5SG\)Y%]9+AA@1.1#*D*X&(X2G( MG<(Y@KC%26D\;VIP"F"V%-DK6S6/A^#CN2$"H@1< []/ "N M)UPP@"L"D^%4QA1MBYB&UU+4@=0R3;\4"D!*3 NDV761Z0XB9";J+.52:"HM M83Q;32H-"2/BU',<47SJ0H 5XA; M\%F:FM^%",RI@G[?:Q(UI*1N;(YU^W45U[[5C-30LM++1>6P>IZ%?3C"C?2=[&"VG,MK=K5)@'-67\Q77D(F MQEIL@LSF]G1E$SNGFF^1-K3*M*2%$@3>R!GI,PB_67>;41,]^'T MSAV?0.HARK5H\8Q)IBGVC$68 $E"8:Q5*5/E*3"-BP 5MTUZW)/Q/*.R)+B. M!L@@3!PI3_ 3H9D1TK7< 1<8 I^WK@N/*X0]$0/9"!QH>5Y\Y239T6MV9/F& M.634&/# 2.B*MF#11,6*RF;II>BR*,/6L?V5I]H=&^Q]&D!8IPIZ1AF?1%3. MHO^Q.G$-)H4R]%>MB%NA/4*V]/"L9W!$?&[S >J#41($&0 7FF'ZF&^!>/5< MN!9VRIH2C?Y5ZBQQ@*A6+GD+C7>I*UTT,1SBT\,Z22R%R70(& '1AAYK)L'P MT&D8&J6*B43B-UP&/'L0B%H_L?5VUB/:9)JU4UFI[0ZPO>WZAFM#[?Z)K/89 M:6R3^??%^9Y!\#&(L,3\HQ?@.TA!752=0'^+A6DA*,8*E9"MC&F.M5196.C, M4'/#8,4A[I#Z/3\)YBO!B5UOH"P?MR@T;68 CJ(JC;AT-*$* =;(@13$-3>G M^J*I3G;YTRR 0N@;?"BA'0HWY)5J!5T#G:P7,U,[A;78Y]04<1TOE9J6R93+ M,B] ])$]=8:I&R8[-HDXBL((VO82BU$\&BZ[+!V,7E 75JU<S1A)L9LK4SV08[ M#]E8WM R0X$4C7:7.LK.[1,%I@2$=:2/] P"T;&R\QYD3M?U MP>K*B-P^LM!@.$'ZZ43LQ9K'6_8!@Y,U':IK>LB1!.G(*5WQKM%O;'I44*T4 MGA78EL8>^Q30_\X+0;\+BHQ84\DS5XDVM/1;Z=[M&-VJI7>Q?'*U]+N M[4N8_Z^Z7N+QAWJ=G4D1^ ?LBH_%(19^3 BH#]CN(7MKL=D^V+;T#MRKMXJVWY7?98A65:X% C.R*_%VQPM:K[S-GKUMU=J"+3"T%9>Z0 M-IW&'J@GK/?9'?I*NON..GV5_7]02P,$% @ &WM75C1S\@K]"0 )C( M D !E>#4M,BYH=&WM6_]/&SD6_SU2_@<]#[\/HKMT(*2\>@S^CI@1=Z;%8SG%%UI. M9X_*WVS]^7/Y?EGZ_YIF1D^5C,GTNQCKG>MEL=/8# MUFEW]I]2@%A,'E7EE\O+0;-Q->-ZSD.1&QGR&,LODG"GU[\&_P?=+ONXPSZK M>"+8C=%"&)R62R/8^_:>6]/GL9%SI47 +@>LL]=I=U^8$5^DYPUY)$76;/ D M8K^)Q,1B+I+#GR"$_U(FD: CVSM=F;Q(:SRU()]%LS'CMX+QT(B(\8R%*D\R M$6.I9A1[K#;T L8ME7\)G8DE-NE4:6ZD2MBVF0GV)HZ^Y^H(R;UW<7RJYBE/ MEKW=BV-*[V^T??8V8#+!SB01(6UL-A;2S!CMGLA8)E-6?KX18:ZE@2\Q_R6Y5"S;C;ND3P) M#5,3MO?+/M(G-,3AQ!&4M4D2*S=H82>M\SIXHS/Z.F.I5ED*P?.,97F:VLA MWHHXF6$E8^^YC%U#[*HZX:8\85/'L..6=-L?%0[;']_O]7IOGO_RX$U'93#XWA)Q@++X^6JF)7I5DR$?Y=< MAS/6Z5JA(%JA2CPZ2;6,6>? /;)VCD08-F*1(88MY:FN,3RVD\KWF'54IU?> TLQ B M64O$1%;P<(8TX8_2+$':MF3^#5/E7,CA7Y?)A;V 0^&. W\ MA%0O)K0.WRGRHX6$BT@2RGUO%))>CK*$*IQ-N,5W@2^=M17BQ ,!XN%:^$IW MZNB$OL("=Z[ S"*>:G?VES%?@&?G^2N8#:MVP;0N%B+94CBQ[3K RDX1NJ@P M;*#"G'Q_(]L>N>)!"N$()1RKXIS8*VM27W$-/4V:C0&J0VB4O@\./-R(BI+F MP:]?5(M0 ON(YV8&^_Q1Z0- "RDD%&5!K%*/)])LS+F!2)GEW!NC'C$1Q@OC M/"H\J4*LKFP"_,%W[.0F<\G$*#KU]NW#C!=60S:J'CLR4(!,?L!.39[J4V*J MZ-PSCJ.EIH)XJP!IO4(=Z'\ 7]=8W0OYPTQ)R[R&JZ1/>.-6$H#,@0H&2*>J0# GWE*(%5+.H(:-VNO7!-L+<\J,@%9 MBD_(KX^+U@ MS1%LC94Q:G[(WA/=,;Q Z/*[?LS1!^SM=,$^4HR,0'!TTA^>L=.SX?#J9#"X M^/C;KUOM+?OYYNKDM/CL:?CS0A7'/,W 2_';$2(C,C-23?L?=>/9T75QAFT3 M0AX7^C JK1W]C0;%CI6C*P.-!C1_OZ;_D03X"5W4J&4,-_W6&@OX,[A)K2Z] MJD#9Z@G$KM:UZ">^!:VK]=-7;+-+QG'V>/7W0A#6?O*1X(_&N2]-E@*".U, M@3<;CS]=_PER4"B ]=%VAQ$]_;T48) M[P.+?%1N&/&:"LLPNR6R!*SM7,[B PD4$0+-\!!PP['Z=XB37BPL-%9SD520YO2A ,Y&G4I;AI:ZZ)Z';1 M]%#W1/UJ*,VR6%@Z'@WCYM+8ALGY"\]6>^&J=X+WV@D[#L'"8LG*20\?SIO H^,MG*B-J&$(5>6N7X[_"%LJQD MQ7W%RKR)G/%>-VI]:3'S4\NR3R;/:3;&-,V,,VU,5:W+V7TT M#/%SH?4!J^?^A[T[O'W**; 0!DOZHME =9KD<'HO (_D^BIG-=CE2LN)"V4 M%JQSM9#82#N,-!##1:-E+193>XM6!&9-(+[6J.NQ6"+)5T,] M&D>64SGC!YI$[HO2WZ@$8)>[Y60^\NQ8DLY3$Y=ZBWR:*%,ZGX@"]W:%9X'N MU@JNJ$A2B+@1DV- KS%3/?V*2,@B:>>TKW[VC 2Q[V? SF.+DPGAUHV)X6^% MU>LNWN%>_A4[UMWI% >=:.VC]V]WKK[R4L7Z3O]'[NM<4 MW,S5=P$3,$[3: )&N<:!>NY>L;#/9X+;C.>'KD-*A.S23:>+$:Z;"#<;U2QV MAUTD;"IO[;T9-0M>+;:^1,I&AU<8CQ""OL"XVN,'S-1#3)6VL"\%-Y\;>8YOBI=4_KEYV^S>$'%2Z3PN)^[3/-[(Y(4*;:&P1_^,>'N1 ML?683/\NZ&T:P&24VB6<,0M>F O4NN[V6ZS\8$O$Q\2?:42$;#A\.J%"?(B MM>\4[_#!4VG^N2OYO[N8Z1RQ3ZZ/.61##M#_>D_S)_?I>O()>$BH,-9"*AX'W!&W5]<3=) :TABNJ,P MO_ZM[B1 (,RH&Q1FV+.72M*7JJ[JIZNJJYO]__5[!GHF#J.6^26F)%(Q1$S- MTJG9^1)S>3N>C_VOM+FQW^50#LJ:[$NLR[E=3"9?7EX2+^F$Y7222J%02/9% MF9A7J-B/+*>F4DKR]ORLJ75)#\>IR3@V-3*L9%#S<7;[XNVP:,LQ:*BH>!)T MDDY.-0UO]5&%\<*YI/YB!#T5(VGE+C:FZLD3@C6J@A^)SH6,^_;"Y)O M0B1JEFMR9Q ]2O[+4 7H-9*44*'SN_/JL%1OT-,3FM43)=)02(G)R4RP#K^1 M^&^?4VZ0TG[2^PUO>X1C).K'R9-+G[_$*I;)813BUP,;I*MYG[[$..GSI#?G MDZ)>TF]V_U_Q.#JDQ-"+J$GX'KK /5)$?;V_A^I5^<=]2CVX_];\2ZT>E_V]H(W,PK/6>ZMG=>P*:#+3#_S431F]0@6%Q ML%$W==(_)8/[%*!=6E7RZJ_< M^R#DM0F/WM*&>M_L8H>P>_5>8J[7")//WM).5=!RY;>5GB)I9N,M2Q\@Q@<& M^1)K@^H5D9*R.;JF/2AR05Y0P^IA<\=[L ,$.+0ME5RGST$]G3+;P(,B,BV3 MR)>T7Q3:2APQ#>0GJNO$E)-"?(2"%VX/VM(\?>_SAD"I0\?J"5V1 *MP:_1W M#)G -71%:#%2&V*ED3KL)T-=S*?7D*[$2E)9(CM*AM@5_0+&$@>6?<*\$@+* MBTRNT4 D@MOL2MQ6LRX>#!=$GVFQ_S7',#A2XS1'F"F!PA^5^'&O>Z8Y3I! M;U!,RK[HLXRH_E.6 ^ *JA$YVL.GP^=4%V_:E#A(LD(B%\!*_30LFH,,TVYJ-'L$,]6$P-QRQEZ_?0PF:8QJ=:S3*C&M'C5_U>VOQV6RWZB&@_>A49@: M4'^&CLU'#QX";-Q/0GWX+?[MVV_%X3TDM"^.#=HQBTB#F4.:<6[9 M101-#!^T+,ZMGGP6*^TS&YOC_<7;N$<-P/!?]"C+,OJ#> 3&2O_YMY)+[>TG M18-@YMBE]_+BD3EW^B8I&UM-&ZY!XE>X(Q?]\07MA>J\*QI(_14+O6A9#@C. M&]L# VN/* .,,G'TK/0K%6^->K7]5IS*HABJ7Y^?U9K-^>;%2?*D^7S>8=:G9X9:YL[E135022$UE,X65 MXF5AB/@!>G5XV3@'.F638ND7?D4AI4IW*1ZO6IHKK%_AI-YK0\]NY./],$CK MQ/IQ8^6:8$3^8W-[O+]8*1\_G;2UA^.[5H_%TUQQ'? Q^.9&@]B6PU>+^"O7 M82X6U',+"FDB_H:4-+(+"%!V M$E^K$_AZ)?W,FN>%1@/M;>'QH7%QUTWWN^\&6B\0_25&^[RH0T\]J-?5\6 MQ!,S"HA#A,5*AZ3EN-@9(%790:+E-3Y_[O(]J5@57[&\:%F#="@36Q!<1 ^C M]8I9O:N[1^/Z\;(PAP4\JM]8Z7QP#M;W%3C?/:P1EU,-&\!7W=02OXT";=7Z M6(/51HP%DO@0C '"##&;:"+RI2,*XN(, 78#/#C;J\5D]"SAN&40Z,TPX+DF M-SE3,?G9QKH>?'XS7V/^^-#-UBS#P#8#@H*_O C5/G?>WL$S<:0J!N,%#GX0 M[]KG^KL)3JM_+5H.$3-?" M@A,S:2Y4?X[BE4.*=T@- N)I$2=:RW)F^MQ2*Z99T>:VW(SZ%+L.2CR=4W/Y MM:XLH:Z$S9-KW*_[6T*:!("?*CA;W48+7E*Z?Z45]5W?3?-/M]H_P;2JADRKLJX[A#'_UQDU MB3)C_Z9&L'/\\G!S^3@WLRJB\T^/ 2V;N-1?B$N-%M?WBU0VG^GTS)T,COI*VL#M]MRA;Z)_0+_J#(Y>-W>N M+,:Q\3>U9X?OJ/%0-XZT[Y??._/F)M0[.,>*FLK^]C-GRV=>;O;9#HB1VMA MI$\T6+R>18P?K"1H$ILZ^D%M&&2=_!;A_-64UVB_Y3__SJO*[AY(CA.#V%W+ M),B4@9T=X:$;KMB20-@A6,HLR!K^A6L%O @XQ!^LA9(>;BI M[D([H"78' 0OVY8!O8N*8L>1BA ?*Z[8V*XWV%]!<"JA9JDY5S=I8BW-^&OI MC4,Y:*R(&;NF'Q-CT0MJ54LKEW7]\N4,SR4_JV59!L&F/'$VOM1&DB04I["; MR>S-7&[GLG>X8.7W6?,(U$(,(MM/YQ3((4Y(H(R:]3! SOU18J1,A]Q2=E'E ML(% . DHN+W$6W7+&&?_:)C[C:4R"UF:ED$U4%BS0>W_ [S6P,DW/[X$I([X\&GL^=]. HF1P7%'',"648#U$E$PJX95<@\J2 MB?K/!96"#RI7#A%V@3@7+D_1"%O;N6RW9R9CU3NIPVXNCTE^H> RFZ[? V2 MO[@VQN#K+!@EH\?5K=;VZR#'*[L&G243_9\+.IEHT*DSYA+GE]#C*A>UE[/S M'Z<7\SG.\DKHF:+NCP:@-(EGMK37 9!?=@8 +28)Y,,"+$M.]/BQ/V^?@SA$ M#PET>,)1KBA^1 R$N Z +5, S-L/BP#TB5LD6M&W2+R2JR[E)"X&BHC+F5X< M; ]9S:07GO9]+:X\\Y-[Q;%(K8LT S,V[ZS[#[8X/DI"2G[Q$G*P/G2(FX-> MRS*VV/9:/J^23SJ[_)/F,E870&^;.,6]KC#B@2LK&#GK'A$F2+ M&]3$;52+M#M7PBE;O&;L^IKAXYZ'>-%J<HP5A*W M:Z[%O1AQEZZ[/F;^"A<"%V?VD?B64CW)E"UM5R%S.PDK$'SZ$&P430+_F8Z? M9N7]5+!-.3;0.78>"8_0G[57]C%$UTU=^-:@=JT!TD12A.C^$19H(D^T320L M4)$JB, ]%Q1V4,>Q7GA7^.BVR&' #.FD34WOA@!OAS.5#1RYB>U-[[:7--H2 MX[:[)WEMD4UDS M]K+IAQCY/:CXY(HM#JC@B4':^],Z\9/+>"<.)N1DOZ/P\G@X>3+< M'.YC.DX\$4^>9F\4DXF(M(0'UR!M64./G :!< -C/S#T@XNEIX;%(?@QWB* MM4"-+<=R_,B&-PI#Y0A='CRZZS?4^OC<6*%IL?@+C!>P0N^W2G5.>IL;2B*E MH)JX'DED4EL(HR!9"U6%\T#EP:1RQR%R%S"QZ%,6JVQ"^0_!NB&BR51BSBG% M9;:Y80OKQ4MO#^Z#W!$AW*EK%'>D:>(;Q4AJO70$I8SUD6AQ(%JT)2J(DTYJ M:F_,H;MR'3!OV)@2R#+*WK9O6FF /!@\3+"BH O*93?/A''+83(K'T!/>*!X M+,*,=.H0Z2"V@5FPN[;HMO!E<0=B^*#\(10U)2H*)+Z27V\A>FZ*T"GRC$(D;Q/3_0 J]/!_BNQR M&$K=$6[+L!$Y>K\@1Y-1VL@ [?@ >\%@=FIH&E_^,KGFP/7.Q ]R@3>JD169%A@P0OV$@IJ>F=X!G. M:= HA#G'X.+I(AI5ZW=IBW*432BRG=%G55 @+K04D&2 ARC)H SY]T4'5^,* MH/./ *UU\+--AX(P'0Z'3K0\H"[0@8T+EZTMA@\B>DO?%C=X>Z.^8K1_5HK. MN_-P%IQO$YWD,R*=FA\QS7UE\F]LDJ>PYWC79:3#.CR.]Q$L?G *R"RA+EZ0 M5<(TA]K>/8C+>\ODPH<"#(_52+Y=I73U?8R\KQPD_6Q<271Y+U:Z] S1:#MT M/XG_9!545T.L*ZN"ZI0*1OH\?[06JNDU$GX,$E; '1<.; @)/::&?OF6=X60 MEZ'K)L&-0FZ M/6BC9L_66_!NWY-7UEOQZ2_[SM^0_^[K=9OWHHGS]K;%BWS.\NJ'TT!=] M>BF)U"!([V/#"\K[.K46Z MV&BCUL#;59,'JOT27>(05^Q%R_:PR[N6 ^3K"]T36W_UVT>Z5Q]EYP'CXO&7 MF/J.,5WH-/2;E^F]PGPK(M<&YUG#0DJ BN+HDV_X'9<;Y^5*[=MUO5(^:^Z@ M^D4EL=R!;E\;LZF//M/Z9A+32T]A9G?!)"Z7ZBQX[1/?REOTR!OEE*6#K^9= MA7#,P:#X87MZBXXHTE*2)3T.*EU'),1TL0TU@U,&\_RYGZ1+BYA+BD%+2M8' MW-<,NABHI53('72>J";6ZO,[D/41=TLQ*G+JUM&W)8Z^I??0I?LJ-_A^USL:O/RHFM<7M_3$O$NELM\'Q]56MF)H["CS MA!N'@[.3PT:Z<*B?U/6'ZM%N[[^'U2/&&^KM<:'SU] <_"EKE1C__.ZL. M>N7&UW[UHI[3#@\NG^\*Y.7Q^?SPJGE"GKX>J=^=6O6I_'#:ZW:_XT$[GGV/=R\/A;NS>K)6_MX].&H_9>O/&=P\N*C]]_BB_WQ6,Y\, MWK4?;FY.[>Z->LP9&]22[O="N6$_-+^EOGC#\?]02P,$% @ &WM75F5Q MFS1+ P K0P !$ !M>6UD+3(P,C,P,C(Q+GAS9+56VW+:,!!];F?Z#ZK? MA3%,+A!H)@V3E!EH,Z$):5\ZPEY $ULRDLRE7U_)%S#78M+R).^>^VW;;0]:VTO=L5*AK-OV;#8K,3XE,RY>9:K_/?EY2>!U/^Y_G@T% [(6D M:O)<72S@="?T/('2#.K!!DZ"6QKQJ:T=&E^I9,!(XA$AX1(\)'(0BTJAL(S" M&#RI9G!MW0E=TS14M0A![E:-76N$[H]N:XD-%H%G.M(@JAKDZ+GR(0"F[K@( M6C DD:^3F$3$IT,*GH44$2-0IL5D2%PXH)3U*&&,ZU;6\Y1:C"T,J>Y5;7C7 M,(=:%]R'[SI79!9ZB+9UC<.^Y?H2L!#UFE:R- I:+];P8$@9C0.ED^(@;.8B M,@7I94QIV)O@G$0DP?O&/L7K4(#4O#CSCC:DQ!2RA^02WXW\8IQ5*CLIJ2'; MH=6>9=/P"$,43U'=G';3DM3<8U9J&PL8-BVSC3@[FE^ZM)+NA@QBI ],4;SS MF[N1!LXDB'"W5+:F7(OP$(2BNB5SHYRD3I6A/^3"(!-'6LC^%R7[9%"T9$T! M_S_6VC'Z^2+3X;!7TY%^;TY00Y?+A4)L:PP/W8')[=WA;BQU@&*^<,;#QH2= M"JXZI;GT5ID626*U \62R'@G)+'G)MX57^Z#FX5IHU=6HIOKK/X* " A@ M%0 &UY;60M,C R,S R,C%?;&%B+GAM;,V=76_CN!6&[POT/[#N30N,XXF# M;9'L9!<93[(P-INDL6>V[:)8T!+C")')@)(3^]^7%$59HG@D)45)SL6,1WP/ M]5)\3%)?QY]^W&U2]$)XEC!Z/CH^^CA"A$8L3NCZ?/1U,;Y8S.;S$-'L;)GHZ*4JUM*70LY3L/B2 MOL^U&>W)OOCN\/Q_:$ ]WGD3EBS'Z;O,UR.=V[XA[SOBASCW1UJ,\^1]1[H6 M^7^QG;BT\-BV27BPF,Q-JDK*)C!"[V4$P,9=U5[2QJU)O* MT9SQ=MOES%C4F9'H:,U>)C%)1-W3J?PPEA^*9HO__#YC8B5PLDY'Z?J,*KP!\XVUMV6K6:6PM_3516O M#HO8!6"T(>,D8UL>D3?U2MTM=)1*1YM4*.22BM#QU\7HAT*#?M.J_WR:'&IQ MT-%B";3=$)HO18V6%C2+776SS93NY7I9$)UL,63VL98@J7'!O9[LD[DU"(MR/-;(C=V#&. WO70WVG;G NLXB"@&>(0 MG"WJ0:B*\L31!:5;G-Z39\:[\&G*7%-C,VG"4M<$Q8C%&(B&TB(E]D3$/[;B MC)WP=-\+14OIF@O JHF&(0N*#KLW$)!*[I>1)<V,BAB0'L@,T4$*D/" MP>;R1:[.Q3)I8&-K>I_PM&QW\5.)@T7(=#B0HB(,R3A/)-5N0_0PU%*ZI@>P M:G)CR((BQNX-9$7)4:'W#\DEC0KL2VK*-Y%JUK0$"[)B0M85"@0.Y 6%2 9J8(\0K,OPCFPW"I*?W TK)J M1Z62!0B*Z:T/$ZGW LELRWG#-3SCP%)G-V5[S%;W9P%=$*#TF&O=M57R!BB> M9J!+FB?Y7CY/=[/=K BW-*XM<<4&9$XS898'P0)@RF1 R9#4(27TTO/Z+@'- MY4.,8'-,F5L"[":;%#0U 9%@-0;0<- 6SY1Z(6(F1B:.TSF-R>YGL@?;U=*Y M90*PV83"$ 5$A=T9@$4I1H4:";D7,.YXLL%\OTBBGJFB+72+!F2TR8:I"@@. MP!I 1ZE&B_G,YTRRQ+MY+$!-'A+U/'@/):#>+2P]MIO, .* T.EV"! D@E S MRB=(8@"P^7EK<^6&2 7,_($)^8% NK M6W['V4M"(WC)#,F] .8ME)C:,-#QVZPCY]J0:SCO(XU:E'>^R71,C^C3-.D M?8A1FO @:1KK'5R4VB<2=RS+7N7@&VV#J\ EPK# ("FZ/V*\#JZHD2N>YFR2@G&!@1 MFL7..MEBJNKC6ED87=PVU.KAXGLM-#Z^R#*[2WKWR"C\@$!;XJJG(7.ZM\WR M('H<,&7V>B%#A<[3U7B982*S#]^U,F&P1TKGJYTZ;N<:LHB-[O($V2R%RH5Z).M!8FV8G[<'T]7RR1/;2>7;8FS.0DP5\U(1GD0; "F M3!:*,L0>T/'T+ZN_(AWEN/MOV))CF3QVL=^L6 IDG[*J7$'085%S8)$$@0+L MRZ3AAJ%2BI361W:JAEE+FN;Q0&T>DV1ZTO?Z.O/0WYE[OH49@B MP L)=IGKH=]FTAS^ZYH@$.@PUCHI*:5(:WV\D'"8LM;]BX"UMT7 NF<1L YQ M$; >N@A8>UL$Z-VJ%"%B7+I=IBP;/)AD0:%"NP/'#.J$'2( M<9W1LDAQ)M/S\TVQ_ROQP=)*0.P/B5I.G/E+W2!<$9HR16UU)L=XJZ]6Z?F.FQW7QH!A '@=,0A\"C M,S)H_"2CD XKKX1Y(>D;2[.M;:LV(&8Z#4+O<)R!>$C=4[A/'M"RV<\=4DH#PL/GJR"##D=9Z86&QP6GZ>9LEE&3P1&2H MW+)@M=ADH2$)B 6;+X"%0HJTU@L+EQO"UV)Z^XFSU_RQS,\*M@U0NV6CTW*3 M$:LT(%:Z_ ',Z!"D8G1*73_P[ X)Q5661;BE%JEC;$"S!C,M74C 0.9:M*0D MDM=;;EB.E@Q]S0C*'PFZ+'^&KIX)7M7CZY=&HDB^$*%6Y33&W(90E]CYKXZ MAEN_/=)2!@%2KSWX=TBJ"*1#'%-S*QCF]?.XPL0\)QOP;8?^$%<$#36O.>K3 M!T'30),F4T58\^2Z"$0RTFWB)UQ Y7AE;#!H+XYHB"$9 6]"RN/Y; M 7YRYVU7:1)=I0S#5UD:&L<9\]KVC&1Y!T% !+1=02GR"B$JE%[Z_S.F3WS[ MG$?[.\XB0N135EDU6O5=?QL8[9:9-S6I2=.@T( X>XM?@,!#%:A6QX?:C.7S M8IY\:%QF@-L0C<< MBDA4A'Y *AC5HCV=GV6'+( D_KR_)P^$R_<.EF27?Q8[>NHXPQ@0Z_KL;7!S MS).YWL @('RK6^A4+T/U"M!*/B-65H%^DY6@HA;;[Y?7-UV+3V*SWB3^6N&, MB"W_!5!+ P04 " <>U=6G%:125,' #-5P %0 &UY;60M,C R,S R M,C%?<')E+GAM;,V<77/B-A2&[SO3_^#2:R"0MMMDD^XD;-AA-KM)0W:W[7) M>?1>QNV1F,JWT6>2TO/H Q54$2/5V^@KX9G;(H>,4Q4-9+K@U%#[1='P>?1[ MI_=F$K7;@'J_4I%(]>5AM*UW;LQ"GW>[R^6R(^0S64KUI#NQ3&$5C@TQF=[6 M=K(ZV?P4Q2\X$T_G[M>$:!I97D*?KS2[;+EV-\TN3SM2S;K]DY->]Y]/M^-X M3E/29L)QBVFK+.5JJ2K7.SL[Z^;?EM(CY6JB>-G&:;?LSK9F^RT+Z'=ZHMFY MSKMW*V-B\K#7-A-Y%>Z_=BEKNTWM7K]]VNNL=-(JX><$E>3T@4XC]]=&;]MJ MNDX3%ZRN^Z([D'9GM+W,B\P5G5ZVG,#6W#\]Z??S>G_=$YGUPNZ4FKE]JA5U M]]I<**JI,+G-6[MAKPA=&;LKT:2LR+4/Z95AQ@DW.TDO:KL]*DMM._9CH=QT MHNP&E_%>R]R1EP7<[[L/CD$_]V__^9XW=#711I'8 ME#5Q,J$\K_^[U1Q(N@WTJB3Q:&NL[M2^XK!/NP&[4G$D54*595W6152\%Z;C M'7*CZ"Z(LA6UXSGCVPA/E4Q]=#8DI*>CNZ!L$\W0O++M)ZX/0TYFU3@/)$"> M/0R@E6ZPB+ZG.E9LX;C4@-U3 OGV4?E6>&L8HVAL<% M3Q$@^%/,D2+H%BD"5T)DA#_0A50UX/>50-Z_8?*N\H:$^>^,*$,57T-('XF! ML'_'A.UQB,3[41&AF>,# 7ZL!A+_ _7"P^,1"?EX3CEWJ1L1H+V\2@_$_@83 MN]_G*P!_\^S.[_;4 F>_4P2(_\_7@O_(+5($[JEB,K&G= 5@?R0&4C_#I.YQ MB,K[1B10VELI./_!AWU@#PGUD.F8\*)'0[M-AW%7R*'(47+.6INHV/^E1(&A M[XBAR%'2T!J+#0,?9$KM=28XJOC54.0H"6B=R8:9WPC#S-K=Z_^ ]="] M1:#L4=)*D%V4$(Q$+-5"[MPN'LC,'H_K@4R"0WI-06@X4/+-%UA'"O/GE@G:"X6B4@Y^1H07@(#-5X*]_S+L?3AVE#RTUN8KP7[Z,NRG<.PHN6BM M34SL _OQ3CW*I><)M%<,18Z2B]98Q 2>GVGNU+V2SZR8"U5'_:@$%#UBBAHV MB[K#%R=YR-Y>*J&\$=/5:G.8G.^E-H3_QQ9U5Y+5>BASQ,0U9+3I&XQ%W-U- M"]]4H@,)E"]*KEIIIVFD+L**$O_NNZ^ D5)0*O,-,SS5KIG'W,I@O=CCU50 MKBB9I,]4TP.OFT2LO8?^SM?@&6PHP^JAC88Q?E/,V!X,9)IF8G./QO-4S".% MXD5)_X+V&D8]EIS%S# Q^V2O$!4CO)ISE0X*&279\QMKF/"]HB[2U%YVY_.X MW"H#=3>=^D;>D!Y*'"77JS>*2WZD=4;52_E7E()& 27M@YIN>IRA<6:'O76O M/WET*V8\H\R1"LH:)>7SF6J8[6?YJ(A;HS=>IQ/)_J%9" :-D>B%S:&/O##3VSEXX]J)D M?#Y32&R+N>'VB+J;<#8C_I5DP0+@=3:8Q -6FUZ_ER_Y<:NW59KW8V@_5&/W M2*' <99(ANPUC3I+F*%)T:4A$T3$-J7:KFOS9.?UI: !P%E#"32-' M'GLX*8;-H\^?5P)YX9C+\S/Q "*6-.!6VTAH*Y'%*.+_.-!-4!\>6 R$4,N*< MUTIK*)!O4JIF=E#[H.32S#=K.T.P/06@T!%GM@:MXL!?_5A'7JQ_"Y*O4(/? M3H"(W6L2Z[4;<>PF4A1GTD.YHRZL]!MMF/R=F5.U>_V4=V9D\[;0 MI(?Z4M HH*2K4-,XY]:=E?S!4^N>#LH;,3&M,H:S9BJ;9_*VEMG_!FP;!1Z_4"G5+EI"H]T M9:YM0T_ABR) <6A\4-\H!,90$::+[I&O6[O!O9>V^,;]M5O^!U!+ 0(4 M Q0 ( !M[5U;QV9AII@H -$^ ) " 0 !E>#4M M,2YH=&U02P$"% ,4 " ;>U=6-'/R"OT) F,@ "0 M@ '-"@ 97@U+3(N:'1M4$L! A0#% @ &WM75K=WZ <7$P BIL L M ( !\10 &9O'-D M4$L! A0#% @ &WM75J*;ZZS^"@ @(8 !4 ( !JRL M &UY;60M,C R,S R,C%?;&%B+GAM;%!+ 0(4 Q0 ( !Q[5U:<5I%)4P< M ,U7 5 " =PV !M>6UD+3(P,C,P,C(Q7W!R92YX;6Q0 52P4& 8 !@!L 0 8CX end